Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 11/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.59 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.58 |
| ▸ | RECQL | P46063 | 1/20 | 0.55 |
| ▸ | POLB | P06746 | 3/20 | 0.55 |
| ▸ | HTR6 | P50406 | 6/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21430924 | 0.91 | MAPT (0.55) | MAPTALDH1A1SIRT6RECQLPOLB | |
| Hydrochloric Acid SCHEMBL23044907 | 0.90 | MAPT (0.54) | MAPTALDH1A1SIRT6RECQLPOLB | |
| SCHEMBL268283 | 0.88 | MAPT (0.61) | MAPTALDH1A1SIRT6SMN1; SMN2CYP1A2 | |
| SCHEMBL13162443 | 0.87 | SIRT6 (0.76) | MAPTALDH1A1SIRT6POLBHTR6 | |
| SCHEMBL19677556 | 0.86 | MAPT (0.70) | MAPTALDH1A1SIRT6SMN1; SMN2MAPK1 | |
| SCHEMBL23316412 | 0.86 | SIRT6 (0.61) | MAPTALDH1A1SIRT6SMN1; SMN2MAPK1 | |
| SCHEMBL7987904 | 0.83 | SIRT6 (0.69) | MAPTALDH1A1SIRT6RECQLPOLB | |
| SCHEMBL5863451 | 0.83 | ADRB1 (0.55) | MAPTALDH1A1POLBMAPK1HTT | |
| SCHEMBL1414539 | 0.81 | MAPT (0.64) | MAPTALDH1A1SIRT6RECQLPOLB | |
| SCHEMBL23316379 | 0.81 | MAPT (0.59) | MAPTALDH1A1SIRT6SMN1; SMN2MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8324216-B2 | Substituted piperazines | CHEMOCENTRYX, INC. (US) | 2012-12-04 | — | — | US | disclosed |
| US-20100240618-A1 | SUBSTITUTED PIPERAZINES | CHEMOCENTRYX, INC. (US) | 2010-09-23 | — | — | US | disclosed |
| US-7589199-B2 | Substituted piperazines | CHEMOCENTRYX, INC. (US) | 2009-09-15 | — | — | US | disclosed |
| EP-1691810-A4 | SUBSTITUTED PIPERAZINES | CHEMOCENTRYX INC (US) | 2009-07-01 | — | — | EP | disclosed |
| EP-1691810-A1 | SUBSTITUTED PIPERAZINES | ChemoCentryx Inc (US) | 2006-08-23 | — | — | EP | disclosed |
| US-20060106218-A1 | Substituted piperazines | CHEMOCENTRYX, INC. (US) | 2006-05-18 | — | — | US | disclosed |
| US-20050256130-A1 | Substituted piperazines | CHEMOCENTRYX, INC. (US) | 2005-11-17 | — | — | US | disclosed |
| WO-2005056015-A1 | SUBSTITUTED PIPERAZINES | CHEMOCENTRYX, INC. (US) | 2005-06-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060106218-A1 | Substituted piperazines | CCR1, CCR3, CCRL2 | MAPT 4063/4885ALDH1A1 951/4885SIRT6 4264/4885 |
| US-20050256130-A1 | Substituted piperazines | CCR1, CCR3, CCRL2 | MAPT 4063/4885ALDH1A1 951/4885SIRT6 4264/4885 |
| US-20100240618-A1 | SUBSTITUTED PIPERAZINES | CCR1, CCR3, CCRL2 | MAPT 4063/4885ALDH1A1 951/4885SIRT6 4264/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.